Inhibitory effect of gold nanoparticles on the D-ribose glycation of bovine serum albumin.

Citation data:

International journal of nanomedicine, ISSN: 1178-2013, Vol: 9, Issue: 1, Page: 5461-9

Publication Year:
2014
Usage 225
Downloads 172
Abstract Views 53
Captures 14
Readers 14
Citations 7
Citation Indexes 7
Repository URL:
http://digitalcommons.uri.edu/chm_facpubs/70; http://digitalcommons.uri.edu/cgi/viewcontent.cgi?article=1070&context=chm_facpubs
PMID:
25473284
DOI:
10.2147/ijn.s70777
PMCID:
PMC4251757; 4251757
Author(s):
Liu, Weixi; Cohenford, Menashi A.; Frost, Leslie; Seneviratne, Champika; Dain, Joel A.
Publisher(s):
Dove Medical Press Ltd.; DigitalCommons@URI
Tags:
Biochemistry, Genetics and Molecular Biology; Chemical Engineering; Materials Science; Chemistry; Pharmacology, Toxicology and Pharmaceutics; Medicine
article description
Formation of advanced glycation end products (AGEs) by nonenzymatic glycation of proteins is a major contributory factor to the pathophysiology of diabetic conditions including senile dementia and atherosclerosis. This study describes the inhibitory effect of gold nanoparticles (GNPs) on the D-ribose glycation of bovine serum albumin (BSA). A combination of analytical methods including ultraviolet-visible spectrometry, high performance liquid chromatography, circular dichroism, and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry were used to determine the extent of BSA glycation in the presence of citrate reduced spherical GNPs of various sizes and concentrations. GNPs of particle diameters ranging from 2 nm to 20 nm inhibited BSA's AGE formation. The extent of inhibition correlated with the total surface area of the nanoparticles. GNPs of highest total surface area yielded the most inhibition whereas those with the lowest total surface area inhibited the formation of AGEs the least. Additionally, when GNPs' total surface areas were set the same, their antiglycation activities were similar. This inhibitory effect of GNPs on BSA's glycation by D-ribose suggests that colloidal particles may have a therapeutic application for the treatment of diabetes and conditions that promote hyperglycemia.